Samsung Bioepis Launches Eylea Biosimilar "Opuviz" in Europe
Direct Sales Launched in Europe
Samsung Bioepis has launched Opuviz (active ingredient: aflibercept), a treatment for ophthalmic diseases, in the European market.
Product image of Opuviz, the Aylia biosimilar launched in Europe by Samsung Bioepis. Samsung Bioepis
View original imageAccording to industry sources on June 1, Samsung Bioepis has introduced the low-concentration formulation (40mg/mL) of Opuviz, the biosimilar of Aflibercept (brand name Eylea), through a direct sales model in Europe.
Opuviz is a biosimilar of Eylea, originally developed by Regeneron in the United States. It is used to treat ophthalmic diseases such as neovascular age-related macular degeneration, and works by inhibiting vascular endothelial growth factor (VEGF) to prevent the formation of abnormal new blood vessels. The annual global sales of the original Eylea are approximately 12 trillion won.
Following the launch of the Lucentis biosimilar Byooviz in Europe in January, the release of Opuviz allows Samsung Bioepis to further expand its portfolio of ophthalmology products.
The company now offers a total of five products through direct sales in Europe. Since launching the Soliris biosimilar Epysqli in 2023, Samsung Bioepis has been building a direct sales system and expanding its business scope beyond development, clinical trials, and regulatory approvals to include commercialization capabilities.
Linda Choi, Executive Vice President and Head of Commercial at Samsung Bioepis, stated, "The launch of Opuviz enables us to offer more treatment options to patients with ophthalmic diseases. Through biosimilars, we aim to address unmet medical needs and contribute to reducing healthcare costs."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Eylea biosimilar from Samsung Bioepis is marketed in Korea under the product name Apilibu, with distribution managed by Samil Pharmaceutical.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.